Persomics is a private life science company specializing in genetic research, with locations in Boston, MA, Cupertino, CA, and Gothenburg, Sweden. The company’s aim is to simplify and expedite the process of discovering the basis of disease, and has established a particular phenotypic screening kit that it uses for this purpose. These kits facilitate the interrogation of thousands of genes in parallel, and therefore pertain to human genome, pharmaceutical and disease model research. By 2013 the drug discovery market had begun shifting from the single to the multi-target paradigm, of which Persomics’ technology is a part. Prior to that time, popular drug discovery efforts focused on identifying single drugs that fit into specific cellular targets; this came to be known as target-based screening (i.e. reverse pharmacology). The multi-target approach entails the understanding that, although one drug compound might fit into a single target, diseases are associated with complex biological processes, and often multiple cellular targets, which are more difficult to unlock. Today phenotypic screening is enjoying a significant resurgence as part of the portfolio of drug discovery strategies leveraged at most companies. This is because phenotypic screening products (such as those offered by Persomics) offer a potentially revolutionary approach to discerning multiple cellular targets as the basis for genetic disease. More information...
According to PR-model, persomics.com is ranked 2,014,679th in multilingual Wikipedia, in particular this website is ranked 1,112,651st in English Wikipedia.
The website is placed before greensocialist.org.uk and after cityofmadisonsd.com in the BestRef global ranking of the most important sources of Wikipedia.
